Matthew Ong spoke with Adam Resnick.
The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.
Caryn Lerman was named director of USC Norris Comprehensive Cancer Center.
The Laura and Isaac Perlmutter Cancer Center at NYU Langone Health received the Comprehensive Cancer Center designation from NCI.
Otis W. Brawley was named the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
In recent years, NCI spending on extramural research has been following the same trajectory as Congressional appropriations for the institute: up, up, up.
Amy Abernethy, a thought leader in the field of evidence generation and the development of real-world evidence, was named principal deputy commissioner at FDA.
The University of Alabama at Birmingham Comprehensive Cancer Center has received a $30 million gift from O'Neal Industries Inc., a family-owned global business based in Birmingham.
As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval.
